AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...

Losing U.S. exclusivity in early 2023, Humira, the top-selling arthritis medication from AbbVie, let biosimilars from Amgen ( ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

These characteristics make dividend growth stocks compelling investments in any market environment. The strategy's success ...